Presented at CYTO 2024, the 37^th annual Congress of the International Society for the Advancement of Cytometry, May 5-8, 2024

The recent announcement by BiolineRx of the FDA approval of APHEXDA™ (motixafortide), represents the first development in stem cell mobilization for the treatment of multiple myeloma to be approved in the U.S. in a decade.  Flow cytometry data generated at Q² Solutions was fundamental to FDA approval, confirming that the apheresis CD34+ stem cell collection goal of ≥ 6 × 10⁶ CD34+ cells/kg had been reached.. The randomized Phase 3 study was run across five countries in USA and Europe, requiring a robust, globally harmonized stem cell assay to assess efficacy results.

This scientific poster details the results of validation, technology transfer, and QC performance during clinical testing, and includes the production of critical efficacy data.

Authors:  
Q² Solutions – Karen Smith, Megan McCausland, Alistair Watt
BioLineRx Ltd. Modi'in, Israel – Ella Sorani, Irit Gliko Kabir, Inbal Goldstein, Debby Ickowicz, Liron Shemesh- Darvish

Complete the form below to access this scientific poster.